Ritter Pharmaceuticals, Inc. (RTTR) financial statements (2021 and earlier)

Company profile

Business Address 2042 CORTE DEL NOGAL
CALIFORNIA, CA 92011
State of Incorp. DE
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 21523716
Cash and cash equivalents 2823716
Short-term investments  7   
Receivables 00   
Prepaid expense  0000
Other undisclosed current assets 1    
Total current assets: 21523716
Noncurrent Assets
Operating lease, right-of-use asset 0
Property, plant and equipment 00000
Other noncurrent assets 00000
Total noncurrent assets: 10000
TOTAL ASSETS: 31523716
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 26331
Accounts payable 15221
Accrued liabilities 01011
Debt 0    
Other liabilities  0000
Total current liabilities: 26331
Noncurrent Liabilities
Total liabilities: 26331
Stockholders' equity
Stockholders' equity attributable to parent, including: 1920415
Preferred stock   5  
Common stock 00000
Additional paid in capital 8072685042
Accumulated other comprehensive loss  (0)   
Accumulated deficit (80)(70)(53)(45)(27)
Other undisclosed stockholders' equity attributable to parent 28   
Total stockholders' equity: 1920415
TOTAL LIABILITIES AND EQUITY: 31523716

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues    00
Other income   (0)00
Cost of revenue
(Cost of Goods and Services Sold)
   (0)(0)(0)
Gross profit:   (0)(0)(0)
Operating expenses (11)(17)(8)(18)(9)
Other undisclosed operating income   000
Operating loss: (11)(17)(8)(18)(9)
Nonoperating income 10000
Debt instrument, convertible, beneficial conversion feature   3  
Net loss attributable to parent: (10)(17)(8)(18)(9)
Preferred stock dividends and other adjustments     (0)
Net loss available to common stockholders, diluted: (10)(17)(8)(18)(9)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (10)(17)(8)(18)(9)
Other undisclosed comprehensive income (loss) 0(0)   
Comprehensive loss, net of tax, attributable to parent: (10)(17)(8)(18)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: